Company: BLCO
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001860742-25-000004
Chunk: 249

Company: Bausch & Lomb Corp
Filing Date: 2025-02-19
Form: 10-K
Item: Item 1A
Chunk 249
---
. Even if we decide in the future to pay a quarterly cash dividend to the holders of our common shares, we may change our dividend policy at any time.We do not expect to pay dividends on our common shares for the foreseeable future. Instead, we anticipate that all of our earnings in the foreseeable future will be used for the operation and growth of our business. As a result, returns on your investment will primarily depend on the appreciation, if any, in the price of our common shares. Even if we decide in the future to pay a quarterly cash dividend to the holders of our common shares, our dividend policy may change at any time. The declaration and payment of dividends to holders of our common shares will be at the discretion of our Board of Directors in accordance with applicable law after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, cash flows, impact on our effective tax rate, indebtedness, legal requirements and other factors that our Board of Directors deems relevant. Payment of dividends may be subject to withholding taxes.General Risk FactorsOur operating results and financial condition may fluctuate.Our operating results and financial condition may fluctuate from quarter to quarter for a number of reasons. In addition, the market price of our common shares and/or debt securities can be volatile. The following events or occurrences, among others, could cause fluctuations in our financial performance and/or the market price of our common shares and/or debt securities from period to period:•development and launch of new competitive products;•the timing and receipt of regulatory approvals or lack of approvals;•costs related to business development transactions;•changes in the amount we spend to promote our products;•delays between our expenditures to acquire new products, technologies or businesses and the generation of revenues from those acquired products, technologies or businesses;

52

•changes in treatment practices of health care and eye care professionals that currently prescribe certain of our products;•increases in the cost of raw materials used to manufacture our products;•actions by the FDA or other regulatory bodies relating to our manufacturers;•manufacturing and supply interruptions;•our responses to price competition;•new legislation that would control or regulate the prices of drugs;•protracted and wide-ranging trade conflicts, including between the United States and China, Canada, Mexico and other countries;•expenditures as a result of legal actions (and settlements thereof), including the defense of our patents and other intellectual property;•market acceptance of our products;•the timing of wholesaler and distributor purchases and success